Top Back to top

Allogeneic hematopoietic stem cell transplantation for the BCR-ABL1 negative myeloproliferative neoplasms in children

Study number:
Short title:
Allo-HSCT for Ph-neg MPN in children
Study status:
Patients selection
Deadline for data collection:
Study design:
retrospective, international, multicenter study
Primary objective:
To evaluate in children transplanted with allogeneic HSC for Ph-neg MPNs:
a) cumulative incidence of relapse (CIR) ;
b) non-relapse mortality (NRM);
d) leukemia-free survival (LFS);
e) event-free survival (EFS);
Key inclusion criteria:
a. Children and adolescents with the classical Ph-neg MPNs (polycytemia vera, PV; essential thrombocythemia, ET; primary myelofibrosis, PMF; post-PV PMF (post-polycythemia (PPV) myelofibrosis (MF)); post-ET PMF( post-essential thrombocythemia (PET) myelofibrosis (MF)), Ph-neg MPN transformed to MDS or acute leukemia);
b. Matched sibling and related or unrelated matched or mismatched donor;
c. Hematopoietic stem cell source - bone marrow, peripheral blood or cord blood;
d. Age ≤ 18 years;
e. Analyzed time period: January 1st 2000 – December 31st 2016.
Principal investigator:
Jacek Wachowiak
Principal investigator email:
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to